Labo Euromedis (XPAR:ALEMG) Debt-to-EBITDA : 0.00 (As of Jun. 2024)

Labo Euromedis Debt-to-EBITDA Chart

Labo Euromedis Annual Data
	Trend	Jul13	Jul14	Jul15	Jul16	Jul17	Dec19	Dec20	Dec21	Dec22	Dec23
Debt-to-EBITDA		Get a 7-Day Free Trial					-11.65	0.52	3.58	-2.91	0.46

Labo Euromedis Semi-Annual Data
	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jan17	Jul17	Jan18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-EBITDA	Get a 7-Day Free Trial															-1.94	9.80	-1.78	0.20	-

Competitive Comparison of Labo Euromedis's Debt-to-EBITDA

For the Medical Distribution subindustry, Labo Euromedis's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labo Euromedis's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Labo Euromedis's Debt-to-EBITDA falls into.

Labo Euromedis Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Labo Euromedis's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Labo Euromedis's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.

Labo Euromedis  (XPAR:ALEMG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Labo Euromedis Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Labo Euromedis's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Labo Euromedis Business Description